Minoxidil has been available for decades, but until recently it was almost exclusively used as a topical treatment. The rise of low-dose oral minoxidil has changed the treatment landscape considerably — offering an alternative route that sidesteps the most common topical limitation (SULT1A1 enzyme activity) while introducing its own considerations.
Here's a grounded comparison of both options, without oversimplifying a genuinely nuanced clinical decision.
How each works
Topical minoxidil is applied directly to the scalp and works through local conversion. The drug is absorbed by scalp skin and converted to minoxidil sulfate by the enzyme SULT1A1 in follicle cells. Minoxidil sulfate then causes vasodilation of follicular blood vessels and prolongs the anagen (growth) phase. Crucially, the efficacy of topical minoxidil depends heavily on your SULT1A1 enzyme activity — patients with low activity (roughly 30–50% of the population) see significantly reduced or absent response.
Oral minoxidil is taken as a low-dose tablet (typically 0.625–2.5 mg for women, 2.5–5 mg for men). It is absorbed gastrointestinally, converted to minoxidil sulfate in the liver (a different, more consistent metabolic pathway), and delivered systemically. Because it doesn't rely on scalp SULT1A1 activity, oral minoxidil works regardless of your enzyme grade. The trade-off is that systemic delivery means the drug reaches everywhere in the body — not just the scalp.
Efficacy: how do they compare?
For patients with high SULT1A1 activity (Grade 3–4), high-concentration topical minoxidil can be highly effective — and may produce results comparable to or exceeding oral at lower concentrations. For Grade 1–2 patients, oral minoxidil typically outperforms topical because it bypasses the conversion bottleneck entirely.
A 2022 systematic review in the Journal of the American Academy of Dermatology found that low-dose oral minoxidil produced meaningful improvements in hair density across both male and female pattern hair loss, with a response profile competitive with or superior to 5% topical in multiple comparative studies. Several small head-to-head trials have found oral 2.5 mg produces greater increases in hair count than topical 5% in women — though these findings should be interpreted with caution as SULT1A1 grades were not controlled for.
Side effects: topical
Topical minoxidil side effects are largely local. The most common:
- Scalp irritation or contact dermatitis: Often caused by propylene glycol (PG) in standard formulations. Compounded PG-free or alcohol-free vehicles reduce this significantly.
- Hypertrichosis: Unwanted facial or body hair growth, occurring in 3–10% of women using topical minoxidil. Typically reverses after stopping.
- Initial shedding: A temporary increase in hair shedding during weeks 4–8. Expected, not alarming, and not a reason to stop.
Side effects: oral
Oral minoxidil's side effects reflect systemic delivery:
- Fluid retention / edema: Mild fluid retention, particularly in the lower extremities, is the most commonly reported side effect. Usually mild at doses used for hair loss. Adding a low-dose diuretic (typically 25 mg spironolactone in women) often resolves this.
- Hypertrichosis: Paradoxically, oral minoxidil causes more body hair growth than topical, since the systemic vasodilation reaches hair follicles throughout the body. At low doses this is usually manageable but worth discussing.
- Blood pressure effects: Minoxidil is a vasodilator originally developed as an antihypertensive. At doses used for hair loss (0.625–2.5 mg), blood pressure effects are typically minimal in normotensive patients — but those with existing hypotension should be monitored.
- Tachycardia / palpitations: Rarely, at higher doses. Usually resolves with dose reduction.
Dosing overview
For women: oral minoxidil is typically started at 0.625 mg/day and may be increased to 1.25–2.5 mg/day based on response and tolerability. Topical formulations range from 2% (FDA-approved) to 5% (off-label) to 8–10% in compounded formulations. For men: oral dosing starts at 2.5 mg and may go to 5 mg; topical is typically 5% standard or 8–10% compounded.
Who is each best for?
Topical is generally preferred as a first-line option for patients with moderate to high SULT1A1 activity, patients who prefer avoiding systemic medication, and patients where localized treatment is sufficient. Oral minoxidil is better suited for patients with low SULT1A1 activity (Grade 1–2), those who have not responded adequately to topical, patients who find daily topical application inconvenient, and those for whom a single daily capsule is a more realistic adherence option. Many patients with moderate disease use both — topical for localized effect and oral for systemic support.
This content is for informational purposes only. Consult a licensed provider before starting any treatment.